Skip to main content
IFRX logo

InflaRx N.V. (IFRX) Stock: Price, Forecast & Analyst Target

InflaRx N.V. (IFRX) — MoonshotScore 56/100 (Fair band), calculated Nov 18, 2026. Price $1.11 (-3.48%), as of the Nov 18, 2026 trading session; market cap $164M.

Educational signal · not a buy or sell recommendation · How to read this

$1.11 −$0.04 (-3.48%) Market Cap $164M

InflaRx N.V. · IFRX · NASDAQ

InflaRx N.V. Their lead product candidate, vilobelimab, is being developed for various autoimmune and inflammatory diseases.

Price as of Nov 18, 2026

Key Statistics

56 of 100

MoonshotScore v2 · InflaRx (IFRX)

Fair
Business Quality Elite (84)
Financial Safety Strained (24)
Valuation Fair (62)
Growth Durability Fading (39)
Momentum Slipping (34)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet and weak growth. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Strained; Valuation: Fair; Growth Durability: Fading; Momentum: Slipping.

  • EPS beat 0 of the last 4 reports
  • Altman Z 2.12 · Piotroski F 2
  • ROE -31.0% · ROA -18.0% · current ratio 7.26

Holding back: balance-sheet strain, weak price trend

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for IFRX (52 recorded, newest six shown)
RecordedScoreBand
54Fair
55Fair
55Fair
55Fair
56Fair
56Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$1.11
Change on the day-3.48%
Market capitalisation$164M—
Shares traded on the day3.05M

Price & events

Other perspectives

Council score for InflaRx (IFRX): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Weak
Valuation Moderate
Growth Durability Weak
Momentum Weak

Legends Council

4 lenses, 4 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Unfavorable read

Read on: Nov 19, 2026

Munger's Mindset

Balance Sheet & Valuation

Financial Health Neutral
Margin of Safety Undervalued
Profit Margin Weak
Debt/Equity Strong
ROE Negative
Gross Margin Negative

Read on: Nov 19, 2026

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

The Munger lens reads the current price as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is InflaRx (IFRX), and what does it report?

Short answer

A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. InflaRx N.V. (IFRX) is listed on NASDAQ. It employs 65 people. The market values it at $164M.

2 · Latest results

What do the latest results show for InflaRx (IFRX)?

Short answer · as of

Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Quarterly income statement — 2 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025€23,830-€12M-€0.18 (diluted)
Q4 FY2025-€33,931-€11M—
3 · Financial strengths and risks

What are the financial strengths and risks for InflaRx (IFRX)?

Short answer

The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, weak price trend. The distress and quality screens read Altman Z 2.12 · Piotroski F 2. Trailing ratios: ROE -31.0% · ROA -18.0% · current ratio 7.26.

Data-derived red flags

  • Negative return on equity (-31.0%) — the business is not currently generating profit on shareholder capital.
  • Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
  • Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
4 · What to check next?

What should you watch next at InflaRx (IFRX)?

Short answer · as of

Analyst estimates on file carry FY2026 revenue $12,825 · EPS -0.21 · 3 analysts. Current published price targets run low $2.00 · high $9.00 · consensus $5.50 · median $5.50 against a quoted price of $1.11 (as of Nov 18, 2026).

What the records here don't tell us

  • The next earnings date is not yet scheduled in the calendar we read.
  • No insider Form 4 transaction falls inside the window this page reads.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does InflaRx compare with its peers?

Short answer

InflaRx's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Eli Lilly and Company (LLY) Named competitor$1382.75 Nov 18, 2026$1.23T98 5-pillar Nov 18, 2026
Regeneron Pharmaceuticals, Inc. (REGN) Named competitor$945.53 Nov 18, 2026$97.8B95 5-pillar Nov 18, 2026
Fennec Pharmaceuticals Inc. (FENC) Same industry, near in market value$13.33 Nov 18, 2026$471M91 5-pillar Nov 18, 2026
Zevra Therapeutics, Inc. (ZVRA) Same industry, near in market value$9.28 Nov 18, 2026$552M91 5-pillar Nov 18, 2026
Protalix BioTherapeutics, Inc. (PLX) Same industry, near in market value$3.02 Nov 18, 2026$255M90 5-pillar Nov 18, 2026
Rigel Pharmaceuticals, Inc. (RIGL) Same industry, near in market value$42.53 Nov 18, 2026$801M88 5-pillar Nov 18, 2026
ImmuCell Corporation (ICCC) Same industry, near in market value$11.25 Nov 18, 2026$102M82 5-pillar Nov 18, 2026
Rallybio Corporation (RLYB) Same industry, near in market value$15.26 Nov 18, 2026$85.5M82 5-pillar Nov 18, 2026
Oramed Pharmaceuticals Inc. (ORMP) Same industry, near in market value$3.89 Nov 18, 2026$169M72 5-pillar Nov 18, 2026
Compugen Ltd. (CGEN) Same industry, near in market value$1.96 Nov 18, 2026$186M69 5-pillar Nov 18, 2026
Climb Bio, Inc. (CLYM) Same industry, near in market value$9.30 Nov 18, 2026$546M68 5-pillar Nov 18, 2026
MeiraGTx Holdings plc (MGTX) Same industry, near in market value$8.32 Nov 18, 2026$813M63 5-pillar Nov 18, 2026
InflaRx (IFRX) — this page$1.11$164M56

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$2.00 – $9.00
Consensus target
$5.50
Median target
$5.50
Revenue estimate
$12,825
EPS estimate
$-0.21

Consensus record · Captured .

Measured against a quoted price of $1.11 (as of Nov 18, 2026).

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held IFRX in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported IFRX in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about InflaRx (IFRX)?

Read these with our analysis →

InflaRx Stock: Key Questions Answered

These answers are editorial: 1 of these 9 answers is drawn from the IFRX research dossier (written May 9, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for IFRX?

IFRX carries the MoonshotScore stated above — the Fair band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.

Is IFRX a good stock to buy?

Stock Expert AI does not rate IFRX buy, sell or hold. InflaRx N.V. carries a MoonshotScore, in the Fair band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the IFRX stock price today?

The last price recorded for InflaRx N.V. (IFRX), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the IFRX price target?

The analyst consensus price target for InflaRx N.V. (IFRX), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What are the main risks for IFRX?

The primary risks for InflaRx N.V. include clinical trial failures, regulatory hurdles, and competition from established pharmaceutical companies. The success of vilobelimab is critical to the company's valuation, and any setbacks in its development could significantly impact the stock price.

What are the key factors to evaluate for IFRX?

InflaRx N.V. (IFRX) holds a MoonshotScore in the moderate range. To weigh it, read the analyst view under Analyst targets & estimates on this page. InflaRx has a co-development agreement with Beijing Defengrei Biotechnology Co. Ltd. and a clinical trial collaboration with Merck & Co. Inc. Not financial advice.

How frequently does IFRX data refresh on this page?

IFRX's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven IFRX's recent stock price performance?

InflaRx N.V. (IFRX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider IFRX overvalued or undervalued right now?

InflaRx N.V. (IFRX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 9, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 17 figures on this page — 10 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.